Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue:
Drug safety advice
- Ketoconazole: restricted indications
- Tazocin (piperacillin/tazobactam): new formulation
- Telbivudine: risk of peripheral neuropathy with pegylated interferon
- Modafinil: serious skin reactions, hypersensitivity, and psychiatric symptoms
Yellow Card scheme update*
- Yellow Card Centres - important contribution to drug safety
Hot topic
- Nasal decongestants that contain pseudoephedrine or ephedrine: update on sales restrictions
Stop Press
- Boots’ Medisure Domiciliary Dosage System (DDS): risk of incorrect dose
- Recent letters to healthcare professionals
Other information from the MHRA
- Injectable medicines for cosmetic procedures: supply and administration
- Earlier access to medicines
- Patient Information Leaflet of the month
*In the first row of the table for this Yellow Card scheme update, the head pharmacist should be Christine Randall only, the email address for the centre should be YCCMersey@lrippu.nhs.uk, and the telephone number should be 0151 794 8206/8122. The telephone number for YCC Scotland (row 3 of table in the article) should be 0131 242 2919.
Drug Safety Update: Volume 1, Issue 8, March 2008 
